ZYDUS LIFESCIENCES | ALKEM LABORATORIES | ZYDUS LIFESCIENCES/ ALKEM LABORATORIES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 16.2 | 21.0 | 77.2% | View Chart |
P/BV | x | 2.9 | 4.8 | 60.9% | View Chart |
Dividend Yield | % | 0.9 | 1.0 | 93.1% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ZYDUS LIFESCIENCES Mar-21 |
ALKEM LABORATORIES Mar-21 |
ZYDUS LIFESCIENCES/ ALKEM LABORATORIES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 509 | 3,150 | 16.2% | |
Low | Rs | 259 | 2,224 | 11.6% | |
Sales per share (Unadj.) | Rs | 147.5 | 741.4 | 19.9% | |
Earnings per share (Unadj.) | Rs | 20.9 | 135.3 | 15.4% | |
Cash flow per share (Unadj.) | Rs | 28.0 | 158.3 | 17.7% | |
Dividends per share (Unadj.) | Rs | 3.50 | 30.00 | 11.7% | |
Avg Dividend yield | % | 0.9 | 1.1 | 81.6% | |
Book value per share (Unadj.) | Rs | 126.9 | 616.8 | 20.6% | |
Shares outstanding (eoy) | m | 1,023.74 | 119.57 | 856.2% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.6 | 3.6 | 71.8% | |
Avg P/E ratio | x | 18.4 | 19.9 | 92.6% | |
P/CF ratio (eoy) | x | 13.7 | 17.0 | 80.9% | |
Price / Book Value ratio | x | 3.0 | 4.4 | 69.5% | |
Dividend payout | % | 16.8 | 22.2 | 75.6% | |
Avg Mkt Cap | Rs m | 393,092 | 321,244 | 122.4% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 22,548 | 16,210 | 139.1% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 151,022 | 88,650 | 170.4% | |
Other income | Rs m | 449 | 2,332 | 19.3% | |
Total revenues | Rs m | 151,471 | 90,982 | 166.5% | |
Gross profit | Rs m | 31,335 | 19,424 | 161.3% | |
Depreciation | Rs m | 7,248 | 2,746 | 264.0% | |
Interest | Rs m | 1,688 | 589 | 286.5% | |
Profit before tax | Rs m | 22,848 | 18,421 | 124.0% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1,472 | 2,243 | 65.6% | |
Profit after tax | Rs m | 21,376 | 16,178 | 132.1% | |
Gross profit margin | % | 20.7 | 21.9 | 94.7% | |
Effective tax rate | % | 6.4 | 12.2 | 52.9% | |
Net profit margin | % | 14.2 | 18.2 | 77.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 87,160 | 69,288 | 125.8% | |
Current liabilities | Rs m | 78,613 | 36,041 | 218.1% | |
Net working cap to sales | % | 5.7 | 37.5 | 15.1% | |
Current ratio | x | 1.1 | 1.9 | 57.7% | |
Inventory Days | Days | 33 | 20 | 170.2% | |
Debtors Days | Days | 76 | 66 | 114.2% | |
Net fixed assets | Rs m | 140,943 | 34,825 | 404.7% | |
Share capital | Rs m | 1,024 | 239 | 428.3% | |
"Free" reserves | Rs m | 128,899 | 73,517 | 175.3% | |
Net worth | Rs m | 129,923 | 73,756 | 176.2% | |
Long term debt | Rs m | 6,095 | 343 | 1,779.6% | |
Total assets | Rs m | 228,103 | 104,114 | 219.1% | |
Interest coverage | x | 14.5 | 32.3 | 45.1% | |
Debt to equity ratio | x | 0 | 0 | 1,010.2% | |
Sales to assets ratio | x | 0.7 | 0.9 | 77.8% | |
Return on assets | % | 10.1 | 16.1 | 62.8% | |
Return on equity | % | 16.5 | 21.9 | 75.0% | |
Return on capital | % | 18.0 | 25.7 | 70.3% | |
Exports to sales | % | 0 | 22.1 | 0.0% | |
Imports to sales | % | 10.5 | 0 | - | |
Exports (fob) | Rs m | NA | 19,555 | 0.0% | |
Imports (cif) | Rs m | 15,911 | NA | - | |
Fx inflow | Rs m | 63,535 | 19,555 | 324.9% | |
Fx outflow | Rs m | 15,911 | 2,467 | 644.8% | |
Net fx | Rs m | 47,624 | 17,088 | 278.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 32,930 | 12,649 | 260.3% | |
From Investments | Rs m | -7,225 | -9,985 | 72.4% | |
From Financial Activity | Rs m | -25,489 | -2,718 | 938.0% | |
Net Cashflow | Rs m | -905 | -17 | 5,261.6% |
Indian Promoters | % | 74.9 | 57.1 | 131.1% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 15.4 | 19.6 | 79.0% | |
FIIs | % | 2.5 | 5.4 | 46.8% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 25.1 | 42.9 | 58.6% | |
Shareholders | 408,017 | 81,869 | 498.4% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ZYDUS LIFESCIENCES With: CIPLA SUN PHARMA LUPIN DR. REDDYS LAB AUROBINDO PHARMA
Indian share markets ended on a negative note today as global cues remained weak.
A look into the company's quarter four financial performance.
As the new variant of Covid-19 emerges, keep an eye on these stocks.
These companies are likely to benefit the most from Covid-19 vaccines.
Here's why Divi's Lab's stock fell over 10% in two days.
For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.
More Views on NewsWe are just two months into 2022 and several penny stocks that we track have already surged 5x.
Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.
A step-by-step method to pick the best penny stocks for the long term.
These penny stocks can become future multibaggers. Watch out for them.
Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?
More